⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Faron Pharmaceuticals and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Faron Pharmaceuticals
↗Turku, Finland
Faron Pharmaceuticals is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on developing novel immunotherapies for cancer. The company leverages its expertise in immunology to modulate the tumor microenvironment, specifically targeting macrophages to overcome treatment resistance in hematological malignancies and solid tumors.
Its lead asset, bexmarilimab, is a first-in-class, humanized monoclonal antibody that binds to Clever-1, an immunosuppressive receptor on macrophages. By reprogramming these cells, Faron aims to enhance the immune system's ability to recognize and destroy cancer cells, offering a potential breakthrough for patients who do not respond to existing immunotherapies.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2003
Ownership:public
Status:operating
FUNDING
Stage:Public
Investors:TAP
STOCK
Exchange:AIM (London), First North (Helsinki)
Ticker:FARN
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2b
Modalities:Monoclonal antibody
Active Trials:10
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:City of Hope (Clinical investigation)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Juho Jalkanen - CEO
Scientific Founders:Markku Jalkanen
LINKS
Website:faron.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Faron Pharmaceuticals. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.